← Oncology Approval Tracker

FDA DECISION ·

Opdivo + chemotherapy

nivolumab with fluoropyrimidine- and platinum-containing chemotherapy · Bristol Myers Squibb

FDA approvalNew or expanded indicationGastric, gastroesophageal junction and esophageal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma treated with nivolumab plus a fluoropyrimidine and platinum regimen.

LAMPGEN ANALYSIS

Why it matters

The action adds PD-1 blockade to chemotherapy in a group of advanced upper gastrointestinal adenocarcinomas.

What research teams should watch

Verify histology and anatomic site, and retain the date-specific FDA indication when comparing biomarker-defined cohorts.

PRIMARY RECORDS

Sources